Mahamaya Lifesciences Limited · BSE:MAHALIFE
Mahamaya Lifesciences — Investor Presentation (August 2026)
29 slides from Mahamaya Lifesciences's investor presentation, Aug 7, 2026
Slide 1: Investor Presentation
Investor Presentation
Slide 2: Disclaimer
Mahamaya Lifesciences Limited (The “Company") is contemplating the potential, subject to necessary approvals, market conditions, and other considerations, of initiating an initial public offering of its equity shares ("IPO") and has submitted the DRHP to the BSE SME Platform of BSE Limited (“BSE SME
Slide 3: Company overview
Mahamaya Lifesciences Limited is an integrated agrochemical company engaged in manufacturing, formulation, and marketing of crop protection and biological solutions for domestic and international markets. Operates a state-of-the-art facility at Dahej, Gujarat, catering to rising demand through large
Slide 4: Key facts and figures
30+ 01 15,817.86 50+ Years of Manufacturing Sq.mts. Product Experience Unit Spread Across Portfolio 04 310+ 90 65% Product Dealers Network Total No. of Top 10 Customer Categories (as of 31st March 2026) Employees Contributes (As on 31st March 2026 FY 2025-26 (In ₹ lakhs) Revenue EBITDA PAT 32,887.30
Slide 5: Company milestones
Conversion of the Listed on Bombay Company from Stock Exchange, private limited to unlocking access to public limited. public capital market 2024 2025. One of the top 10 Pesticides and Insecticides Factory completed Manufacturers. The Company and production of a Certified by “Industry received CTE f
Slide 6: Strengths
Strengths Experienced Management Team Led by Mr. Krishnamurthy Ganesan, with over three decades Strong Brand Portfolio of expertise in the crop protection industry. Products marketed under recognized, farmer-trusted Mrs. Lalitha Krishnamurthy oversees HR, legal, financing, brands across India. and i
Slide 7: Financial Overview
FINANCIAL OVERVIEW
Slide 8: FY-2027 Outlook & Strategic Priorities
FY-2027 Outlook & Strategic Priorities IV E S T O R U P D A TE Revenue & Margin Growth Outlook 02 Completion of IPO Capex 03 Capacity Expansion & Market 01 Opportunities Revenue growth in line with RHP projections Capex program funded via IPO proceeds Expanded capacity positions us to capture at ~30
Slide 9: Financial Snapshot
Financial Snapshot Figures in ₹ lakhs, Margin in % Investor Presentation 9
Slide 10: Domestic Sales and Export
Figures in ₹ lakhs In Domestic Export % Sales Sales 97.8 99.3 95.0 95.3 4 3 9 0 4.9 4. 2.1 0.6 1 7 7 6 FY2 FY2 FY2 3 4 5 Investor Presentation 10
Slide 11: IPO Fund Utilisation & Capex Progress
IPO Fund Utilisation & Capex Progress
Slide 12: Utilization of IPO Proceeds (₹61.96 Crore)
Utilization of IPO Proceeds (₹61.96 Crore) As on 31 March 2026 Amount Object Allocated Utilised Balance Working Capital 18.00 18.00 - General 8.26 8.26 - 29.17, 47% Corporate Purpose 32.79, 53% Warehouse & 2.53 1.65 0.87 Machinery Formulation 3.76 0.50 3.25 Plant Technical Plant 29.42 0.76 28.66 Key
Slide 13: Business Overview
BUSINESS OVERVIEW. <~
Slide 14: Business Performance & Operational Highlights
Business Performance & Operational Highlights INV E S T O R U P D A TE 01 Agrochemical Industry Trends 02 Domestic & Export Business 03 New Product Introductions Update •India agrochemicals market: Domestic revenue growth broadly in ~US$9.6Bn (2026) → ~US$13.3Bn by line with overall RHP guidance of
Slide 15: Investor Presentation
• State-of-the-art • Dedicated R& • Positioned as a biological • Consistent engagement • Registrations in more • Consistent engagement manufacturing facility laboratory at D Dahej crop care through regular countries across South East through regular at Dahej, Gujarat, equipped for innovation company
Slide 16: Growth Initiatives
Growth Initiatives Regulatory pipeline, export markets & innovation roadmap Regulatory Approvals & Product Pipeline Export Expansion & New Market R&D, Innovation & Digital 01 In India 02 Development 03 Transformation New Molecule & Process R&D 31 39 US$110Bn+ Global crop protection market (2026), gr
Slide 17: Geopolitical Impact on Indian Agrochemicals
Geopolitical Impact on Indian Agrochemicals Surge in Input Costs Supply Chain Disruptions Crude-linked chemical prices rising. Fertilizer and agrochemical intermediates facing inflationary pressure. Restricted trader outes (Middle East corridor) impacting raw material availability. Higher logistics
Slide 18: Production capacity and actual production
Actual Production (In Kg) Actual Production (In Ltr) Solid formulations 10,40,000Kg 11,69,8 11,58,4 19 47 per Annum capacity 5,36,74 0 Liquid 2,94,75 2,72,076 2,37,64 Formulations 0 2,07,25 6 7 42,5G5 13,00,000L Per Annum capacity June 30, FY25 FY24 FY23 June 30, FY25 FY24 FY23 2025 2025 **Total Sol
Slide 19: Product Offering
Product Offering Investor Presentation 19
Slide 20: R&D and quality assurance capabilities
Team of qualified scientists (Ph.D. & M.Sc.) focused on new formulations, patentable processes, and cost optimization. Equipped with advanced systems like Dyno Mill, Fluidized Bed Dryer, and Air Jet Mill for scalable product development. Developed many technical processes also Developing many formul
Slide 21: Slide 21
Slide 22: India Agri-Input Production Overview
India Agri-Input Production Overview India Agri-Input Production Overview Production of Agri – Inputs in India by Type (Thousand Tonnes) 922 873 856 781 745 735 • 624 • 591 514 • • 450 • • • 315 • • • • 111 91 72 76 85 63 62 2019 2021 2023 2025F 2027F 2029F Biofertilizer Pesticides Bio Stimulants In
Slide 23: Growth Catalysts in India's Agrochemical Industry
a Growth Catalysts in India’s a Mahafilaya: Key Growth Drivers Population growth and limited land drive higher agrochemical use to raise productivity Food Demand Growing preference for Grew 8.1% CAGR (FY19- eco-friendly pest FY23); projected to control offers strong reach #385 bn by 2025 potential B
Slide 24: CSR, Recognition and People Excellence
CSR, Recognition and People Excellence
Slide 25: CSR Expenditure & Payment Status (FY 2025-26)
CSR Expenditure & Payment Status (FY 2025-26)
Slide 26: Awards and Recognition
Awards and Recognition Investor Presentation 26
Slide 27: Slide 27
Slide 28: Board of Directors
Mr. Krishnamurthy Mr. Prashant Mrs. Lalitha Ganesan Krishnamurthy Krishnamurthy Managing Director Executive Director and CFO Whole-time Director 30+ Years of Experience 20+ Years of Experience 22+ Years of Experience Dr. Gopal Krishna Raju Dr. Charudatta Digambar Mr. Sekhar Kavasseri Independent Dir
Slide 29: Contact details
‘An1S0 $0012015 cetfed company al, MahaMaya. MAHANAVA LIFESCIENCES, Mahamaya Lifesciences Ltd Unit No: DPT - 033, Ground Floor, Plot No: 79 - 80, DLF Prime Tower, F - Block, Okhla, Phase - 1 New Delhi - 110020, India. Phone: +91-Il-46561474 / Email: info@mahamayalifesciences.com i Website: www.maham
Mahamaya Lifesciences — Investor Presentation (August 2026) on 6ix